A lower depression score does not answer every recovery question. Can the person concentrate, maintain relationships, manage responsibilities, and enjoy daily life? A 2025 treatment study shows how functioning, workplace productivity, and absence can produce different results. For families comparing private care, the lesson is straightforward: ask what improved, not simply whether a score fell.
Key findings
2.0 additional weeks: functional remission with the esketamine strategy in a secondary analysis of the 32-week ESCAPE-TRD trial.
0.7 to 3.3 weeks: the reported confidence interval for that difference.
43.2%: the relative increase in weeks of functional remission. The absolute difference remains two weeks.
No conventionally significant difference in absenteeism: the confidence interval for that separate outcome included zero. These are different findings from the same study. [1]
The same trial tells more than one story
| Outcome | Difference | 95% confidence interval |
|---|---|---|
| Weeks in functional remission | 2.0 more weeks | 0.7 to 3.3 more weeks |
| Absenteeism-related lost weeks | 1.1 fewer weeks | 2.9 fewer to 0.7 more weeks |
| Overall work-productivity lost weeks | 2.3 fewer weeks | 3.9 to 0.7 fewer weeks |
The functioning and overall productivity comparisons favored the esketamine strategy. The absence-only interval included no difference. Source: Vieta and colleagues, 2025. [1]
The trial compared esketamine nasal spray with quetiapine extended release, each alongside an antidepressant. It was open-label with blinded raters and funded by Janssen EMEA. Participants knew their treatment, which matters when interpreting self-reported functioning. [2]
The useful conclusion is not that one treatment transforms every dimension of life. It is that different measures capture different changes. A favorable result on one should not become a claim about all the others.
What a symptom score can tell us
Symptom questionnaires provide valuable structured information. Their meaning still depends on the measure, the population, and the purpose for which they are used.
The original PHQ-9 validation involved 6,000 patients, with 580 in an independent interview comparison. At a threshold of ten, the study reported 88% sensitivity and 88% specificity for major depression. Those are historical validation findings, not an 88% chance that any particular person with a positive screen has the diagnosis. [4]
A screening result can support further assessment. Change on a questionnaire can help track symptoms. Neither supplies a complete account of diagnosis, relationships, work, physical health, or quality of life.
The outcome labels are not interchangeable
| Measure | Question | Not the same as |
|---|---|---|
| Screening | Is further assessment warranted? | A complete diagnosis |
| Symptoms | Did measured symptoms change? | Improvement in every area of life |
| Functioning | What can the person do day to day? | Absence of symptoms |
| Quality of life | How does the person experience life? | An employer’s productivity estimate |
| Satisfaction | How was the service experienced? | A demonstrated treatment effect |
A patient may improve in one area while struggling in another. Those differences should prompt discussion rather than be forced into a single success label.
Averages and thresholds also tell different stories. A group average can improve while some people deteriorate. A binary recovery rate can miss substantial improvement among people who remain above its threshold.
A broader framework does not require a proprietary score
ICHOM’s depression and anxiety outcome set distinguishes symptoms, functioning, work status, and disease-related absence. It was developed with clinicians, measurement specialists, and patient representatives. [3]
A clinic can explain which established measures it uses and why they fit its patients. It does not need a mysterious composite score to recognize that recovery has several dimensions.
Implementation still matters. Naming an instrument on a website does not establish that assessments are consistent, that the population is appropriate, or that follow-up occurs. A framework is a starting point for measurement, not proof that the service has measured well.
Returning to work is not the only legitimate goal
An employer may focus on attendance. A patient may prioritize concentration, sleep, manageable responsibilities, or participation in family life. Those interests can overlap without being identical.
For an executive or founder, a thoughtful decision to reduce responsibilities should not automatically count as failure. Returning to the same workload should not automatically count as full recovery either.
The clinical studies cited here did not recruit representative high-net-worth or leadership samples. Their relevance to those clients is the distinction between outcome domains, not a special estimate of executive performance.
A useful care plan records the person’s priorities and revisits them as circumstances change. It should leave room for improvement to mean a different pattern of life, not only a return to the previous one.
Families add a perspective, not a replacement outcome
Relatives may notice changes that a clinician cannot observe during appointments. With appropriate consent, that information can improve the assessment. It should not silently replace the patient’s experience.
A family may feel reassured while the person remains distressed. It may also remain worried despite meaningful improvement. Those differences are worth discussing rather than averaging away.
For family-funded care, clarify the roles of the patient, payer, relatives, and clinical team before treatment. Financial responsibility does not automatically settle what information each person receives or whose goals define success.
The final session is not the final observation
A discharge score describes a particular point. It does not establish what happens after returning to travel, work, or family demands.
Later assessments should use predefined intervals and state how many eligible patients participated. Changing instruments without explanation can make a series difficult to interpret. Missing observations should remain visible rather than be assumed to represent recovery.
Further treatment matters too. If someone receives substantial care after the initial program, later improvement should not automatically be credited entirely to the first provider.
Physical health belongs in the comparison
A 2026 study of 44,957 NHS Talking Therapies patients associated physical long-term conditions with higher odds of planned discharge but lower odds of reliable recovery. That is another example of engagement and clinical outcomes differing. [5]
The study is observational. It does not prove causation or describe wealthy patients specifically. It does reinforce why comparisons should consider who was treated, not only the final percentage.
For someone choosing private care, ask whether the assessment considers relevant mental and physical needs together. A symptom instrument is useful information within that assessment, not a substitute for the full picture.
Five questions to bring to a treatment discussion
| Question | What it clarifies |
|---|---|
| What are we measuring? | Symptoms, functioning, experience, or another outcome |
| What matters to the patient? | The person’s own priorities |
| When will we reassess? | The observation period |
| What if measures disagree? | How the clinical plan is reviewed |
| What happens after discharge? | Continuity and later outcomes |
These are proposed discussion questions, not a validated clinic ranking. Providers should also disclose deterioration and unwanted effects rather than rely solely on favorable experiences.
What the evidence cannot tell us
The trial findings do not prove better executive performance or the value of every multimodal treatment package. The questionnaire validation does not provide individual diagnostic certainty. No THE BALANCE patient outcomes were analyzed. Each source answers a defined question, and the results should not be combined into one invented effect.
The bottom line
Keep measuring symptoms, but do not stop there. The question is what changed, for whom, and over what period, and whether that change matters in the life the person returns to. A recovery report should make those distinctions easier to understand, not hide them behind one impressive score.
For journalists
Key comparison: two additional weeks in functional remission did not establish a conventionally significant difference in absence alone in the 2025 trial analysis.
Important caveat: a secondary analysis of a specific depression trial, not a study of executive performance.
Suggested attribution: THE BALANCE analysis of published functioning and recovery measures.
Methodology and sources
This narrative analysis separates trial outcomes, questionnaire validation, reporting frameworks, and observational associations. Confidence intervals retain their original outcome units. No combined effect or proprietary recovery score was calculated.
- Vieta and colleagues. Functioning and workplace productivity in ESCAPE-TRD. 2025.
- Reif and colleagues. Esketamine nasal spray versus quetiapine for treatment-resistant depression. 2023.
- ICHOM. Depression and anxiety patient-centered outcome measures.
- Kroenke and colleagues. PHQ-9 validity study. 2001.
- Verbist and Lorimer. Physical long-term conditions and psychological treatment outcomes. 2026.
